These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14978874)

  • 21. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C.
    Nattermann J; Zimmermann H; Iwan A; von Lilienfeld-Toal M; Leifeld L; Nischalke HD; Langhans B; Sauerbruch T; Spengler U
    Hepatology; 2006 Oct; 44(4):945-54. PubMed ID: 17006905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunology of hepatitis C: clinical significance of T cell response].
    Shin EC
    Korean J Hepatol; 2006 Jun; 12(2):140-53. PubMed ID: 16804339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronic hepatitis C: virologic and immunologic aspects].
    Moriya K; Koike K
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):405-7. PubMed ID: 15359831
    [No Abstract]   [Full Text] [Related]  

  • 24. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore.
    Winslow M; Subramaniam M; Ng WL; Lee A; Song G; Chan YH
    Singapore Med J; 2007 Jun; 48(6):504-8. PubMed ID: 17538746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
    Hallinan R; Byrne A; Amin J; Dore GJ
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus reinfection in injection drug users.
    Grebely J; Conway B; Raffa JD; Lai C; Krajden M; Tyndall MW
    Hepatology; 2006 Nov; 44(5):1139-45. PubMed ID: 17058216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies?
    Missale G; Cariani E; Ferrari C
    Dig Liver Dis; 2004 Nov; 36(11):703-11. PubMed ID: 15570998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus (HCV): a review of immunological aspects.
    Irshad M; Khushboo I; Singh S; Singh S
    Int Rev Immunol; 2008; 27(6):497-517. PubMed ID: 19065353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anti-viral immune responses against hepatitis C virus].
    Imawari M
    Uirusu; 2002 Jun; 52(1):151-6. PubMed ID: 12227166
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hepatitis C--a health problem also in Norway].
    Vik IS; Skaug K; Dalgard O; Steen TW; Hoddevik G
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):563-6. PubMed ID: 18311199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The affect of chronic hepatitis C infection on dendritic cell function: a summary of the experimental evidence.
    Ryan EJ; O'Farrelly C
    J Viral Hepat; 2011 Sep; 18(9):601-7. PubMed ID: 21794024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile.
    Gelderblom HC; Nijhuis LE; de Jong EC; te Velde AA; Pajkrt D; Reesink HW; Beld MG; van Deventer SJ; Jansen PL
    Liver Int; 2007 Sep; 27(7):944-53. PubMed ID: 17696933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral evolution of hepatitis C in injection drug users.
    Dove L; Phung Y; Bzowej N; Kim M; Monto A; Wright TL
    J Viral Hepat; 2005 Nov; 12(6):574-83. PubMed ID: 16255758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clearance of hepatitis C virus after newly acquired infection in injection drug users.
    Jauncey M; Micallef JM; Gilmour S; Amin J; White PA; Rawlinson W; Kaldor JM; van Beek I; Dore GJ
    J Infect Dis; 2004 Oct; 190(7):1270-4. PubMed ID: 15346337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.
    López-Labrador FX; He XS; Berenguer M; Cheung RC; González-Candelas F; Wright TL; Greenberg HB
    J Med Virol; 2004 Apr; 72(4):575-85. PubMed ID: 14981760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dendritic cell: the immune system's adjuvant--a strategy to develop a HCV vaccine?
    Larsson M
    Gastroenterology; 2006 Feb; 130(2):603-6. PubMed ID: 16472613
    [No Abstract]   [Full Text] [Related]  

  • 37. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C.
    Heeg MH; Ulsenheimer A; Grüner NH; Zachoval R; Jung MC; Gerlach JT; Raziorrouh B; Schraut W; Horster S; Kauke T; Spannagl M; Diepolder HM
    Gastroenterology; 2009 Oct; 137(4):1280-8.e1-6. PubMed ID: 19596013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug abuse, innate immunity and hepatitis C virus.
    Zhang T; Li Y; Ho WZ
    Rev Med Virol; 2006; 16(5):311-27. PubMed ID: 16933366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural killer cells: primary target for hepatitis C virus immune evasion strategies?
    Golden-Mason L; Rosen HR
    Liver Transpl; 2006 Mar; 12(3):363-72. PubMed ID: 16498647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis.
    Kamal SM; Graham CS; He Q; Bianchi L; Tawil AA; Rasenack JW; Khalifa KA; Massoud MM; Koziel MJ
    J Infect Dis; 2004 Apr; 189(7):1140-50. PubMed ID: 15031780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.